Meningococcal B Vaccination: Bexsero Dosing

Meningococcal B Vaccination: Bexsero Dosing

On August 19, 2024, the Food and Drug Administration approved a new dosing schedule for GSK meningococcal B (menB) vaccine, Bexsero. 

The 1 month interval between dose 1 and 2 is no longer licensed, and has been replaced by a 6 month interval between dose 1 and 2.  With the new dosing schedule, if a second dose is given earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose.

We will issue an updated advisory after the October 2024 Advisory Committee on Immunization Practices (ACIP) meeting if they offer new guidance on how to approach adolescents that have already received Bexsero on the previously approved interval (one month between dose 1 and 2). 

View the updated package insert for Bexsero dosing and schedule intervals below.

Individuals at Increased Risk 

Immunocompromised people and those at high risk of menB disease should receive a 3-dose schedule with doses given at 0, 1–2, and 6-month intervals. If the second dose of a 3-dose schedule is delayed and administered 6 months or longer after the first dose, the third dose is not needed.

Additional Resources